The Experts below are selected from a list of 1020 Experts worldwide ranked by ideXlab platform
Stefano Omboni - One of the best experts on this subject based on the ideXlab platform.
-
SYMPOSIUM MIGRAINE AND ITS VARIETIES Gender and triptan efficacy: a pooled analysis of three double- blind, randomized, crossover, multicenter, Italian studies
2016Co-Authors: Flavia Franconi, Stefano Omboni, Gianni Allais, Chiara Benedetto, Vincenzo Tullo, Giorgio Reggiardo, Cinzia Finocchi, Ilaria Campesi, G BussoneAbstract: -
SYMPOSIUM: OPEN QUESTIONS ON MIGRAINE Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double-blind, randomized, multicenter, Italian study
2016Co-Authors: Vincenzo Tullo, Stefano Omboni, Gianni Allais, Dario Zava, Chiara Benedetto, Marcella Curone, Michel D Ferrari, Bruno Colombo, G BussoneAbstract:The Author(s) 2012. This article is published with open access at Springerlink.com Abstract Migraine with aura affects *20–30 % of mi-graineurs and it is much less common than migraine without aura. The aim of this study was to compare the efficacy of Frovatriptan 2.5 mg and zolmitriptan 2.5 mg in the treatment of migraine with aura. Analysis was carried out in a subset of 18 subjects with migraine with aura (HIS criteria) out of the 107 enrolled in a multicenter, randomized, double-blind, cross-over study. According to the study design, each patient had to treat three episodes of migraine in no more than 3 months with one drug, before switching to the other treatment. The rate of pain-free episodes at 2 h was significantly (p \ 0.05) larger under Frovatriptan (45.8 %) than under zolmitriptan (16.7 %). Pain free at 4 h, pain relief at 2 and 4 h and recurrent episodes were similar between the two treat-ments, while sustained pain-free episode was significantly (p \ 0.05) more frequent during Frovatriptan treatment (33.3 vs. 8.3 % zolmitriptan). Our study suggests that Frovatriptan is superior to zolmitriptan in the immediate treatment of patients with migraine with aura, and it is capable of maintaining its acute analgesic effect over 48 h
-
Efficacy of Frovatriptan as compared to other triptans in migraine with aura
Journal of Headache and Pain, 2015Co-Authors: Stefan Evers, Lidia Savi, Stefano Omboni, Carlo Lisotto, Giorgio Zanchin, Lorenzo PinessiAbstract:The treatment of migraine attacks with aura by triptans is difficult since triptans most probably are not efficacious when taken during the aura phase. Moreover, there are insufficient data from randomised studies whether triptans are efficacious in migraine attacks with aura when taken during the headache phase. In this metaanalysis, we aimed to compare the efficacy of Frovatriptan versus rizatriptan, zolmitriptan, and almotriptan. Five double-blind, randomized, controlled crossover trials were pooled. All trials had an identical design. Patients were asked to treat three consecutive migraine attacks with Frovatriptan 2.5 mg and three consecutive migraine attacks with a comparative triptan (rizatriptan 10 mg; zomitriptan 2.5 mg; almotriptan 12.5 mg). In this analysis, 117 migraine attacks with aura could be included (intention-to-treat population). The mean headache intensity after 2 hours was 1.2 +/- 1.0 for Frovatriptan and 1.6 +/- 1.0 for the other triptans (p
-
efficacy of Frovatriptan as compared to other triptans in migraine with aura
Journal of Headache and Pain, 2015Co-Authors: Stefan Evers, Lidia Savi, Stefano Omboni, Carlo Lisotto, Giorgio Zanchin, Lorenzo PinessiAbstract:The treatment of migraine attacks with aura by triptans is difficult since triptans most probably are not efficacious when taken during the aura phase. Moreover, there are insufficient data from randomised studies whether triptans are efficacious in migraine attacks with aura when taken during the headache phase. In this metaanalysis, we aimed to compare the efficacy of Frovatriptan versus rizatriptan, zolmitriptan, and almotriptan. Five double-blind, randomized, controlled crossover trials were pooled. All trials had an identical design. Patients were asked to treat three consecutive migraine attacks with Frovatriptan 2.5 mg and three consecutive migraine attacks with a comparative triptan (rizatriptan 10 mg; zomitriptan 2.5 mg; almotriptan 12.5 mg). In this analysis, 117 migraine attacks with aura could be included (intention-to-treat population). The mean headache intensity after 2 hours was 1.2 +/- 1.0 for Frovatriptan and 1.6 +/- 1.0 for the other triptans (p<0.05); all triptans showed significant improvement of headache. Frovatriptan resulted in significantly lower relapse rates at 24 hours and 48 hours when taken in migraine attacks with aura. Our data suggest that Frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura. This is of particular importance for those many patients who have migraine attacks both without and with aura.
-
efficacy of Frovatriptan vs other triptans in weekend migraine pooled analysis of three double blind randomized crossover multicenter studies
Brain disorders & therapy, 2014Co-Authors: Carlo Lisotto, Mario Guidotti, Lidia Savi, Stefano Omboni, Lorenzo Pinessi, Giorgio ZanchinAbstract:Background: Migraine attacks usually occur at any time, in particular either during days off or workdays. Limited evidence is available on the efficacy of antimigraine drugs in patients whose attacks occur on weekends. Objective: To evaluate the efficacy of four different triptans in weekend vs. workday migraine attacks through a pooled analysis of individual data of three randomized, double-blind, crossover studies. Methods: Subjects with a history of migraine with or without aura were randomized to Frovatriptan 2.5 mg or rizatriptan 10 mg (study 1), Frovatriptan 2.5 mg or zolmitriptan 2.5 mg (study 2), Frovatriptan 2.5 mg or almotriptan 12.5 mg (study 3). Each patient was requested to treat up to 3 attacks with each drug during both 3 month periods, as established by the crossover trial protocol. In this retrospective analysis the migraine attacks occurring on workdays were differentiated from those occurring on weekends. The efficacy of the drugs during weekends and workdays was compared. Results: Of the 346 intention-to-treat population patients, 188 (54%) had migraine attacks also on weekends. Overall, a total of 569 attacks occurred during weekends and 1,281 during workdays. Proportion of pain-free at 2 hours did not significantly differ between weekend and workday attacks for Frovatriptan (26% vs. 27%) as well as for comparators (34% vs. 32%). Headache relief episodes were also similarly represented between weekend and nonweekend attacks (Frovatriptan: 40% vs. 42% and comparators: 49% vs. 43%, p=NS). Conversely, the relapse rate within 48 hours for weekend attacks compared to workday attacks was significantly lower with Frovatriptan (17% vs. 30%, p<0.05), while this finding was not observed for comparators (weekends 34% vs. workdays 40%, p=NS). Conclusions: Our study provides the first evidence that Frovatriptan represents a particularly favorable option for treating weekend migraine attacks.
Lidia Savi - One of the best experts on this subject based on the ideXlab platform.
-
ORIGINAL A double-blind, randomized, multicenter, Italian study
2016Co-Authors: Marco Bartolini, Lidia Savi, Biagio Panascia, Luigi Alberto Pini, Grazia Sances, Maria Adele, Giamberardino Carlo, Lisotto Paolo Martelletti, Davide Moscato, Patrizia SantoroAbstract:of Frovatriptan versus almotriptan for the acute treatment of migrain
-
Efficacy of Frovatriptan as compared to other triptans in migraine with aura
Journal of Headache and Pain, 2015Co-Authors: Stefan Evers, Lidia Savi, Stefano Omboni, Carlo Lisotto, Giorgio Zanchin, Lorenzo PinessiAbstract:The treatment of migraine attacks with aura by triptans is difficult since triptans most probably are not efficacious when taken during the aura phase. Moreover, there are insufficient data from randomised studies whether triptans are efficacious in migraine attacks with aura when taken during the headache phase. In this metaanalysis, we aimed to compare the efficacy of Frovatriptan versus rizatriptan, zolmitriptan, and almotriptan. Five double-blind, randomized, controlled crossover trials were pooled. All trials had an identical design. Patients were asked to treat three consecutive migraine attacks with Frovatriptan 2.5 mg and three consecutive migraine attacks with a comparative triptan (rizatriptan 10 mg; zomitriptan 2.5 mg; almotriptan 12.5 mg). In this analysis, 117 migraine attacks with aura could be included (intention-to-treat population). The mean headache intensity after 2 hours was 1.2 +/- 1.0 for Frovatriptan and 1.6 +/- 1.0 for the other triptans (p
-
efficacy of Frovatriptan as compared to other triptans in migraine with aura
Journal of Headache and Pain, 2015Co-Authors: Stefan Evers, Lidia Savi, Stefano Omboni, Carlo Lisotto, Giorgio Zanchin, Lorenzo PinessiAbstract:The treatment of migraine attacks with aura by triptans is difficult since triptans most probably are not efficacious when taken during the aura phase. Moreover, there are insufficient data from randomised studies whether triptans are efficacious in migraine attacks with aura when taken during the headache phase. In this metaanalysis, we aimed to compare the efficacy of Frovatriptan versus rizatriptan, zolmitriptan, and almotriptan. Five double-blind, randomized, controlled crossover trials were pooled. All trials had an identical design. Patients were asked to treat three consecutive migraine attacks with Frovatriptan 2.5 mg and three consecutive migraine attacks with a comparative triptan (rizatriptan 10 mg; zomitriptan 2.5 mg; almotriptan 12.5 mg). In this analysis, 117 migraine attacks with aura could be included (intention-to-treat population). The mean headache intensity after 2 hours was 1.2 +/- 1.0 for Frovatriptan and 1.6 +/- 1.0 for the other triptans (p<0.05); all triptans showed significant improvement of headache. Frovatriptan resulted in significantly lower relapse rates at 24 hours and 48 hours when taken in migraine attacks with aura. Our data suggest that Frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura. This is of particular importance for those many patients who have migraine attacks both without and with aura.
-
efficacy of Frovatriptan vs other triptans in weekend migraine pooled analysis of three double blind randomized crossover multicenter studies
Brain disorders & therapy, 2014Co-Authors: Carlo Lisotto, Mario Guidotti, Lidia Savi, Stefano Omboni, Lorenzo Pinessi, Giorgio ZanchinAbstract:Background: Migraine attacks usually occur at any time, in particular either during days off or workdays. Limited evidence is available on the efficacy of antimigraine drugs in patients whose attacks occur on weekends. Objective: To evaluate the efficacy of four different triptans in weekend vs. workday migraine attacks through a pooled analysis of individual data of three randomized, double-blind, crossover studies. Methods: Subjects with a history of migraine with or without aura were randomized to Frovatriptan 2.5 mg or rizatriptan 10 mg (study 1), Frovatriptan 2.5 mg or zolmitriptan 2.5 mg (study 2), Frovatriptan 2.5 mg or almotriptan 12.5 mg (study 3). Each patient was requested to treat up to 3 attacks with each drug during both 3 month periods, as established by the crossover trial protocol. In this retrospective analysis the migraine attacks occurring on workdays were differentiated from those occurring on weekends. The efficacy of the drugs during weekends and workdays was compared. Results: Of the 346 intention-to-treat population patients, 188 (54%) had migraine attacks also on weekends. Overall, a total of 569 attacks occurred during weekends and 1,281 during workdays. Proportion of pain-free at 2 hours did not significantly differ between weekend and workday attacks for Frovatriptan (26% vs. 27%) as well as for comparators (34% vs. 32%). Headache relief episodes were also similarly represented between weekend and nonweekend attacks (Frovatriptan: 40% vs. 42% and comparators: 49% vs. 43%, p=NS). Conversely, the relapse rate within 48 hours for weekend attacks compared to workday attacks was significantly lower with Frovatriptan (17% vs. 30%, p<0.05), while this finding was not observed for comparators (weekends 34% vs. workdays 40%, p=NS). Conclusions: Our study provides the first evidence that Frovatriptan represents a particularly favorable option for treating weekend migraine attacks.
-
Efficacy of Frovatriptan vs. Other Triptans in Weekend Migraine: Pooled Analysis of Three Double-Blind, Randomized, Crossover, Multicenter Studies
Brain Disorders & Therapy, 2014Co-Authors: Carlo Lisotto, Mario Guidotti, Lidia Savi, Stefano Omboni, Lorenzo Pinessi, Giorgio ZanchinAbstract:Background: Migraine attacks usually occur at any time, in particular either during days off or workdays. Limited evidence is available on the efficacy of antimigraine drugs in patients whose attacks occur on weekends. Objective: To evaluate the efficacy of four different triptans in weekend vs. workday migraine attacks through a pooled analysis of individual data of three randomized, double-blind, crossover studies. Methods: Subjects with a history of migraine with or without aura were randomized to Frovatriptan 2.5 mg or rizatriptan 10 mg (study 1), Frovatriptan 2.5 mg or zolmitriptan 2.5 mg (study 2), Frovatriptan 2.5 mg or almotriptan 12.5 mg (study 3). Each patient was requested to treat up to 3 attacks with each drug during both 3 month periods, as established by the crossover trial protocol. In this retrospective analysis the migraine attacks occurring on workdays were differentiated from those occurring on weekends. The efficacy of the drugs during weekends and workdays was compared. Results: Of the 346 intention-to-treat population patients, 188 (54%) had migraine attacks also on weekends. Overall, a total of 569 attacks occurred during weekends and 1,281 during workdays. Proportion of pain-free at 2 hours did not significantly differ between weekend and workday attacks for Frovatriptan (26% vs. 27%) as well as for comparators (34% vs. 32%). Headache relief episodes were also similarly represented between weekend and nonweekend attacks (Frovatriptan: 40% vs. 42% and comparators: 49% vs. 43%, p=NS). Conversely, the relapse rate within 48 hours for weekend attacks compared to workday attacks was significantly lower with Frovatriptan (17% vs. 30%, p
Lorenzo Pinessi - One of the best experts on this subject based on the ideXlab platform.
-
Efficacy of Frovatriptan as compared to other triptans in migraine with aura
Journal of Headache and Pain, 2015Co-Authors: Stefan Evers, Lidia Savi, Stefano Omboni, Carlo Lisotto, Giorgio Zanchin, Lorenzo PinessiAbstract:The treatment of migraine attacks with aura by triptans is difficult since triptans most probably are not efficacious when taken during the aura phase. Moreover, there are insufficient data from randomised studies whether triptans are efficacious in migraine attacks with aura when taken during the headache phase. In this metaanalysis, we aimed to compare the efficacy of Frovatriptan versus rizatriptan, zolmitriptan, and almotriptan. Five double-blind, randomized, controlled crossover trials were pooled. All trials had an identical design. Patients were asked to treat three consecutive migraine attacks with Frovatriptan 2.5 mg and three consecutive migraine attacks with a comparative triptan (rizatriptan 10 mg; zomitriptan 2.5 mg; almotriptan 12.5 mg). In this analysis, 117 migraine attacks with aura could be included (intention-to-treat population). The mean headache intensity after 2 hours was 1.2 +/- 1.0 for Frovatriptan and 1.6 +/- 1.0 for the other triptans (p
-
efficacy of Frovatriptan as compared to other triptans in migraine with aura
Journal of Headache and Pain, 2015Co-Authors: Stefan Evers, Lidia Savi, Stefano Omboni, Carlo Lisotto, Giorgio Zanchin, Lorenzo PinessiAbstract:The treatment of migraine attacks with aura by triptans is difficult since triptans most probably are not efficacious when taken during the aura phase. Moreover, there are insufficient data from randomised studies whether triptans are efficacious in migraine attacks with aura when taken during the headache phase. In this metaanalysis, we aimed to compare the efficacy of Frovatriptan versus rizatriptan, zolmitriptan, and almotriptan. Five double-blind, randomized, controlled crossover trials were pooled. All trials had an identical design. Patients were asked to treat three consecutive migraine attacks with Frovatriptan 2.5 mg and three consecutive migraine attacks with a comparative triptan (rizatriptan 10 mg; zomitriptan 2.5 mg; almotriptan 12.5 mg). In this analysis, 117 migraine attacks with aura could be included (intention-to-treat population). The mean headache intensity after 2 hours was 1.2 +/- 1.0 for Frovatriptan and 1.6 +/- 1.0 for the other triptans (p<0.05); all triptans showed significant improvement of headache. Frovatriptan resulted in significantly lower relapse rates at 24 hours and 48 hours when taken in migraine attacks with aura. Our data suggest that Frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura. This is of particular importance for those many patients who have migraine attacks both without and with aura.
-
efficacy of Frovatriptan vs other triptans in weekend migraine pooled analysis of three double blind randomized crossover multicenter studies
Brain disorders & therapy, 2014Co-Authors: Carlo Lisotto, Mario Guidotti, Lidia Savi, Stefano Omboni, Lorenzo Pinessi, Giorgio ZanchinAbstract:Background: Migraine attacks usually occur at any time, in particular either during days off or workdays. Limited evidence is available on the efficacy of antimigraine drugs in patients whose attacks occur on weekends. Objective: To evaluate the efficacy of four different triptans in weekend vs. workday migraine attacks through a pooled analysis of individual data of three randomized, double-blind, crossover studies. Methods: Subjects with a history of migraine with or without aura were randomized to Frovatriptan 2.5 mg or rizatriptan 10 mg (study 1), Frovatriptan 2.5 mg or zolmitriptan 2.5 mg (study 2), Frovatriptan 2.5 mg or almotriptan 12.5 mg (study 3). Each patient was requested to treat up to 3 attacks with each drug during both 3 month periods, as established by the crossover trial protocol. In this retrospective analysis the migraine attacks occurring on workdays were differentiated from those occurring on weekends. The efficacy of the drugs during weekends and workdays was compared. Results: Of the 346 intention-to-treat population patients, 188 (54%) had migraine attacks also on weekends. Overall, a total of 569 attacks occurred during weekends and 1,281 during workdays. Proportion of pain-free at 2 hours did not significantly differ between weekend and workday attacks for Frovatriptan (26% vs. 27%) as well as for comparators (34% vs. 32%). Headache relief episodes were also similarly represented between weekend and nonweekend attacks (Frovatriptan: 40% vs. 42% and comparators: 49% vs. 43%, p=NS). Conversely, the relapse rate within 48 hours for weekend attacks compared to workday attacks was significantly lower with Frovatriptan (17% vs. 30%, p<0.05), while this finding was not observed for comparators (weekends 34% vs. workdays 40%, p=NS). Conclusions: Our study provides the first evidence that Frovatriptan represents a particularly favorable option for treating weekend migraine attacks.
-
Efficacy of Frovatriptan vs. Other Triptans in Weekend Migraine: Pooled Analysis of Three Double-Blind, Randomized, Crossover, Multicenter Studies
Brain Disorders & Therapy, 2014Co-Authors: Carlo Lisotto, Mario Guidotti, Lidia Savi, Stefano Omboni, Lorenzo Pinessi, Giorgio ZanchinAbstract:Background: Migraine attacks usually occur at any time, in particular either during days off or workdays. Limited evidence is available on the efficacy of antimigraine drugs in patients whose attacks occur on weekends. Objective: To evaluate the efficacy of four different triptans in weekend vs. workday migraine attacks through a pooled analysis of individual data of three randomized, double-blind, crossover studies. Methods: Subjects with a history of migraine with or without aura were randomized to Frovatriptan 2.5 mg or rizatriptan 10 mg (study 1), Frovatriptan 2.5 mg or zolmitriptan 2.5 mg (study 2), Frovatriptan 2.5 mg or almotriptan 12.5 mg (study 3). Each patient was requested to treat up to 3 attacks with each drug during both 3 month periods, as established by the crossover trial protocol. In this retrospective analysis the migraine attacks occurring on workdays were differentiated from those occurring on weekends. The efficacy of the drugs during weekends and workdays was compared. Results: Of the 346 intention-to-treat population patients, 188 (54%) had migraine attacks also on weekends. Overall, a total of 569 attacks occurred during weekends and 1,281 during workdays. Proportion of pain-free at 2 hours did not significantly differ between weekend and workday attacks for Frovatriptan (26% vs. 27%) as well as for comparators (34% vs. 32%). Headache relief episodes were also similarly represented between weekend and nonweekend attacks (Frovatriptan: 40% vs. 42% and comparators: 49% vs. 43%, p=NS). Conversely, the relapse rate within 48 hours for weekend attacks compared to workday attacks was significantly lower with Frovatriptan (17% vs. 30%, p
-
DOI 10.1007/s10194-011-0347-z LETTER TO THE EDITOR When to use Frovatriptan in migraine? A reply
2013Co-Authors: Lidia Savi, Stefano Omboni, Lorenzo Pinessi, Marco Bartolini, Brigida Fierro, M. BartoliniAbstract:We read with interest the comments of Dr. Tfelt-Hansen [1] on the two recently published randomized controlled trials comparing patients ’ preference (primary end-point) and efficacy (secondary end-points) of Frovatriptan with respect to rizatriptan [2] and almotriptan [3]. In both studies, Frovatriptan showed similar preference and shortterm efficacy outcomes (pain relief and pain free episodes at 2 h) with respect to the other two triptans. The principal concern of Dr. Tfelt-Hansen was the very early use of Frovatriptan in these studies, making their results hardly comparable with those of previous randomized controlled trials [4–6], where patients waited until the headache was moderate or severe. In our studies [2, 3], patients were instructed to take one dose of study medication as early as possible after the onset of migraine and to treat at least 1 out of three attacks, but severity of headache at the time of drug intake was in the majority of patients moderate or severe. As a matter of fact, in the study by Savi et al. [2] 78 % of attacks treated with Frovatriptan an
Carlo Lisotto - One of the best experts on this subject based on the ideXlab platform.
-
Efficacy of Frovatriptan as compared to other triptans in migraine with aura
Journal of Headache and Pain, 2015Co-Authors: Stefan Evers, Lidia Savi, Stefano Omboni, Carlo Lisotto, Giorgio Zanchin, Lorenzo PinessiAbstract:The treatment of migraine attacks with aura by triptans is difficult since triptans most probably are not efficacious when taken during the aura phase. Moreover, there are insufficient data from randomised studies whether triptans are efficacious in migraine attacks with aura when taken during the headache phase. In this metaanalysis, we aimed to compare the efficacy of Frovatriptan versus rizatriptan, zolmitriptan, and almotriptan. Five double-blind, randomized, controlled crossover trials were pooled. All trials had an identical design. Patients were asked to treat three consecutive migraine attacks with Frovatriptan 2.5 mg and three consecutive migraine attacks with a comparative triptan (rizatriptan 10 mg; zomitriptan 2.5 mg; almotriptan 12.5 mg). In this analysis, 117 migraine attacks with aura could be included (intention-to-treat population). The mean headache intensity after 2 hours was 1.2 +/- 1.0 for Frovatriptan and 1.6 +/- 1.0 for the other triptans (p
-
efficacy of Frovatriptan as compared to other triptans in migraine with aura
Journal of Headache and Pain, 2015Co-Authors: Stefan Evers, Lidia Savi, Stefano Omboni, Carlo Lisotto, Giorgio Zanchin, Lorenzo PinessiAbstract:The treatment of migraine attacks with aura by triptans is difficult since triptans most probably are not efficacious when taken during the aura phase. Moreover, there are insufficient data from randomised studies whether triptans are efficacious in migraine attacks with aura when taken during the headache phase. In this metaanalysis, we aimed to compare the efficacy of Frovatriptan versus rizatriptan, zolmitriptan, and almotriptan. Five double-blind, randomized, controlled crossover trials were pooled. All trials had an identical design. Patients were asked to treat three consecutive migraine attacks with Frovatriptan 2.5 mg and three consecutive migraine attacks with a comparative triptan (rizatriptan 10 mg; zomitriptan 2.5 mg; almotriptan 12.5 mg). In this analysis, 117 migraine attacks with aura could be included (intention-to-treat population). The mean headache intensity after 2 hours was 1.2 +/- 1.0 for Frovatriptan and 1.6 +/- 1.0 for the other triptans (p<0.05); all triptans showed significant improvement of headache. Frovatriptan resulted in significantly lower relapse rates at 24 hours and 48 hours when taken in migraine attacks with aura. Our data suggest that Frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura. This is of particular importance for those many patients who have migraine attacks both without and with aura.
-
efficacy of Frovatriptan vs other triptans in weekend migraine pooled analysis of three double blind randomized crossover multicenter studies
Brain disorders & therapy, 2014Co-Authors: Carlo Lisotto, Mario Guidotti, Lidia Savi, Stefano Omboni, Lorenzo Pinessi, Giorgio ZanchinAbstract:Background: Migraine attacks usually occur at any time, in particular either during days off or workdays. Limited evidence is available on the efficacy of antimigraine drugs in patients whose attacks occur on weekends. Objective: To evaluate the efficacy of four different triptans in weekend vs. workday migraine attacks through a pooled analysis of individual data of three randomized, double-blind, crossover studies. Methods: Subjects with a history of migraine with or without aura were randomized to Frovatriptan 2.5 mg or rizatriptan 10 mg (study 1), Frovatriptan 2.5 mg or zolmitriptan 2.5 mg (study 2), Frovatriptan 2.5 mg or almotriptan 12.5 mg (study 3). Each patient was requested to treat up to 3 attacks with each drug during both 3 month periods, as established by the crossover trial protocol. In this retrospective analysis the migraine attacks occurring on workdays were differentiated from those occurring on weekends. The efficacy of the drugs during weekends and workdays was compared. Results: Of the 346 intention-to-treat population patients, 188 (54%) had migraine attacks also on weekends. Overall, a total of 569 attacks occurred during weekends and 1,281 during workdays. Proportion of pain-free at 2 hours did not significantly differ between weekend and workday attacks for Frovatriptan (26% vs. 27%) as well as for comparators (34% vs. 32%). Headache relief episodes were also similarly represented between weekend and nonweekend attacks (Frovatriptan: 40% vs. 42% and comparators: 49% vs. 43%, p=NS). Conversely, the relapse rate within 48 hours for weekend attacks compared to workday attacks was significantly lower with Frovatriptan (17% vs. 30%, p<0.05), while this finding was not observed for comparators (weekends 34% vs. workdays 40%, p=NS). Conclusions: Our study provides the first evidence that Frovatriptan represents a particularly favorable option for treating weekend migraine attacks.
-
Efficacy of Frovatriptan vs. Other Triptans in Weekend Migraine: Pooled Analysis of Three Double-Blind, Randomized, Crossover, Multicenter Studies
Brain Disorders & Therapy, 2014Co-Authors: Carlo Lisotto, Mario Guidotti, Lidia Savi, Stefano Omboni, Lorenzo Pinessi, Giorgio ZanchinAbstract:Background: Migraine attacks usually occur at any time, in particular either during days off or workdays. Limited evidence is available on the efficacy of antimigraine drugs in patients whose attacks occur on weekends. Objective: To evaluate the efficacy of four different triptans in weekend vs. workday migraine attacks through a pooled analysis of individual data of three randomized, double-blind, crossover studies. Methods: Subjects with a history of migraine with or without aura were randomized to Frovatriptan 2.5 mg or rizatriptan 10 mg (study 1), Frovatriptan 2.5 mg or zolmitriptan 2.5 mg (study 2), Frovatriptan 2.5 mg or almotriptan 12.5 mg (study 3). Each patient was requested to treat up to 3 attacks with each drug during both 3 month periods, as established by the crossover trial protocol. In this retrospective analysis the migraine attacks occurring on workdays were differentiated from those occurring on weekends. The efficacy of the drugs during weekends and workdays was compared. Results: Of the 346 intention-to-treat population patients, 188 (54%) had migraine attacks also on weekends. Overall, a total of 569 attacks occurred during weekends and 1,281 during workdays. Proportion of pain-free at 2 hours did not significantly differ between weekend and workday attacks for Frovatriptan (26% vs. 27%) as well as for comparators (34% vs. 32%). Headache relief episodes were also similarly represented between weekend and nonweekend attacks (Frovatriptan: 40% vs. 42% and comparators: 49% vs. 43%, p=NS). Conversely, the relapse rate within 48 hours for weekend attacks compared to workday attacks was significantly lower with Frovatriptan (17% vs. 30%, p
-
DOI 10.1007/s10194-010-0243-y ORIGINAL A double-blind, randomized, multicenter, Italian study
2013Co-Authors: Lidia Savi, Stefano Omboni, Carlo Lisotto, Lorenzo Pinessi, Giorgio Zanchin, Dario Zava, Michel D FerrariAbstract:of Frovatriptan versus rizatriptan for the acute treatment of migrain
John C. Campbell - One of the best experts on this subject based on the ideXlab platform.
-
treatment response and tolerability of Frovatriptan in patients reporting short or long duration migraines at baseline
Current Medical Research and Opinion, 2010Co-Authors: Leslie Kelman, Samira Q. Harper, John C. CampbellAbstract:AbstractObjectives:Compare migraine duration with Frovatriptan (versus baseline) in migraineurs reporting long- (24−72 h) or short-duration (<24 h) migraines at baseline.Methods:Post hoc analysis of two postmarketing surveillance studies of migraineurs in German primary care clinics using Frovatriptan (2.5 mg) to treat a single migraine attack. Using case-report forms, physicians recorded migraine characteristics at baseline (aura, duration, frequency, severity) and with Frovatriptan (duration, severity, and recurrence). Patients and physicians rated Frovatriptan effectiveness and tolerability versus previous therapy; physicians recorded adverse reactions. The primary analysis was change in migraine duration with Frovatriptan versus baseline.Results:At baseline, 44.2% (7178/16 253) and 55.8% (9075/16 253) of patients reported short- and long-duration migraines, respectively; long-duration migraines were more often frequent (≥3/months; 55.5% [4893/8811] vs. 30.6% [2132/6973]; p < 0.001; 95% CI, 23.5–26.5%)...
-
safety and tolerability of Frovatriptan in the acute treatment of migraine and prevention of menstrual migraine results of a new analysis of data from five previously published studies
Gender Medicine, 2010Co-Authors: Anne E Macgregor, John C. Campbell, Stephen Pawsey, Xiaojun HuAbstract:Abstract Background: Triptans are a recommended first-line treatment for moderate to severe migraine. Objective: Using clinical trial data, we evaluated the safety and tolerability of Frovatriptan as acute treatment (AT) and as short-term preventive (STP) therapy for menstrual migraine (MM). Methods: Data from 2 Phase III AT trials (AT1: randomized, placebo controlled, 1 attack; AT2: 12-months, noncomparative, open label) and 3 Phase IIIb STP trials in MM (MMP1 and MMP2: randomized, placebo controlled, double blind, 3 perimenstrual periods; MMP3: open label, noncomparative, 12 perimenstrual periods) were analyzed. In AT1, patients treated each attack with Frovatriptan 2.5 mg, sumatriptan 100 mg, or placebo. In AT2, they used Frovatriptan 2.5 mg. In MMP1 and MMP2, women administered Frovatriptan 2.5 mg for 6 days during the perimenstrual period, taking a loading dose of 2 or 4 tablets on day 1, followed by once-daily or BID Frovatriptan 2.5 mg, respectively; in MMP3, they used BID Frovatriptan 2.5 mg. In AT1, which was previously published in part, group differences in adverse events (AEs) were analyzed using the Fisher exact test, and response rates were compared using logistic regression. Post hoc analyses of sustained pain-free status with no AEs (SNAE) and sustained pain response with no AEs (SPRNAE) were performed using a 2-sample test for equality of proportions without continuity correction. For AT2 and the STP studies, data were summarized using descriptive statistics. Results of individual safety analyses for the STP studies were previously reported; the present report includes new results from a pooled analysis of MMP1 and MMP2 and a new analysis of MMP3 in which AEs were coded using Medical Dictionary for Regulatory Activities version 8.0. Results: AT1 included 1206 patients in the safety group; AT2 included 496. In the STP studies, safety data were collected for 1487 women. In AT1 and AT2, 85.6% and 88.3%, respectively, of enrolled patients were women. Overall, AEs were generally mild to moderate (AT studies: 82.3%-90.0%; STP studies: 78.9%89.5%). In AT1, 27.3% (131/480) of Frovatriptan patients, 33.4% (161/482) of sumatriptan patients, and 14.8% (36/244) of placebo patients experienced an AE considered possibly or probably related to treatment (P Conclusions: In randomized controlled trials and 12-month open-label studies, Frovatriptan was well tolerated in these women during AT and STP therapy for MM. Subgroup analyses provide preliminary evidence of tolerability in women using ECCs and in women with comorbidities that do not contraindicate triptan use but may be suggestive of cardiovascular risk.
-
Original article Treatment response and tolerability of Frovatriptan in patients reporting short- or long-duration migraines at baseline
2010Co-Authors: Leslie Kelman, Samira Q. Harper, John C. CampbellAbstract:Objectives: Compare migraine duration with Frovatriptan (versus baseline) in migraineurs reporting long- (24� 72 h) or short-duration (524 h) migraines at baseline. Methods: Post hoc analysis of two postmarketing surveillance studies of migraineurs in German primary care clinics using Frovatriptan (2.5 mg) to treat a single migraine attack. Using case-report forms, physicians recorded migraine characteristics at baseline (aura, duration, frequency, severity) and with Frovatriptan (duration, severity, and recurrence). Patients and physicians rated Frovatriptan effectiveness and tolerability versus previous therapy; physicians recorded adverse reactions. The primary analysis was change in migraine duration with Frovatriptan versus baseline. Results: At baseline, 44.2% (7178/16 253) and 55.8% (9075/16 253) of patients reported short- and long-duration migraines, respectively; long-duration migraines were more often frequent (� 3/months; 55.5% [4893/ 8811] vs. 30.6% [2132/6973]; p50.001; 95% CI, 23.5–26.5%), severe (61.7% [5584/9047] vs. 33.9% [2427/7156];p50.001; 95% CI, 26.3–29.3%), and accompanied by aura (46.8% [4199/8977] vs. 31.3% [2215/7088]; p50.001; 95% CI, 14.0–17.0%). Mean (SD) onset of Frovatriptan effect was51 h; 72.3% (11 592/16 040) of patients required only one Frovatriptan tablet. With Frovatriptan, patients were 26.8-fold more likely to experience decreased versus increased headache duration (p50.001; 95% CI, 23.5–30.2) and 76.5% of patients reporting long-duration migraines at baseline experienced short-duration migraines. Most patients (87–90%) and physicians (70–75%) rated Frovatriptan more effective and tolerable than previous therapies. Conclusion: Patients with more severe migraine characteristics at baseline were more likely to have attacks lasting � 24 h. When using Frovatriptan, patients were 26.8-fold more likely to experience decreased versus increased headache duration. Frovatriptan might be a good option for patients with long-duration or recurrent migraine attacks. The post hoc design and analysis of a single migraine attack are possible study limitations.
-
scheduled short term prevention with Frovatriptan for migraine occurring exclusively in association with menstruation
Headache, 2009Co-Authors: Stephen D Silberstein, Todd Berner, John Tobin, Qinfang Xiang, John C. CampbellAbstract:Objective.— This post hoc subgroup analysis evaluated scheduled short-term preventive Frovatriptan therapy for women with migraine occurring exclusively in association with menstruation (occurring day −2 to +3; day 1 = menses start, no migraines outside this window). Background.— A previously published randomized, double-blind, placebo-controlled 3-way crossover trial assessed the efficacy and safety of a scheduled 6-day preventive regimen with Frovatriptan for the treatment of menstrual migraine; the study population included women experiencing both menstrual and non-menstrual migraine and women experiencing only menstrual migraine. Methods.— Women received each treatment (placebo, Frovatriptan 2.5 mg once daily, and Frovatriptan 2.5 mg twice daily) once over 3 perimenstrual periods in randomized sequence. For this subset analysis, screening questions were used to identify women with migraine occurring exclusively in association with menstruation. Efficacy was evaluated by occurrence and severity of migraine, functional impairment, and rescue medication use. Adverse events and tolerability were also assessed. Results.— Among 179 patients, the mean age (SD) was 37.3 (7.7) years and mean menstrual migraine history was 10.6 (8.7) years. Significantly fewer women experienced menstrual migraine during treatment with Frovatriptan twice daily (37.7%, P < .001) or once daily (51.3%, P = .002) than during treatment with placebo (67.1%); a significant dose response was noted (P = .01, twice daily vs once daily). Significant treatment differences were also found for several secondary endpoints, but the data from this post hoc analysis must be interpreted with caution. Frovatriptan was well tolerated and most adverse events were mild or moderate and similar to those reported with the acute treatment of migraine with Frovatriptan; the most common adverse events were nausea, dizziness, and headache. Conclusions.— Scheduled short-term preventive Frovatriptan therapy effectively reduced the occurrence of menstrual migraine in women with attacks occurring exclusively in association with menstruation.
-
Postmarketing migraine survey of Frovatriptan: effectiveness and tolerability vs previous triptans, NSAIDs or a combination.
Current Medical Research and Opinion, 2009Co-Authors: Roger K. Cady, Beverly A. Jones, James Banks, John C. CampbellAbstract:AbstractObjective:Compare the effectiveness and tolerability of current therapy with Frovatriptan 2.5-mg tablets (in 1–3 migraines) in patients with migraine previously using other triptans, analgesics/nonsteroidal anti-inflammatory drugs (NSAIDs), or triptans and NSAIDs (T+NSAIDs).Research design and methods:Subanalysis of a postmarketing survey study in patients with migraine managed at primary care facilities in Germany.Main outcome measures:A total of 5025 patients rated the effectiveness and tolerability of previous therapy (triptans; T+NSAIDs; NSAIDs) and current therapy with Frovatriptan; physicians rated only Frovatriptan effectiveness and tolerability (1 = Very Good, 2 = Good, 3 = Satisfactory, 4 = Poor).Results:Of 7107 patients initially surveyed, 5025 were identified for this subanalysis as previously using NSAIDs (n = 2890), triptans (n = 1418) or T + NSAIDs (n = 717). The mean (SD) age was 42.3 (11.9) years. At baseline, patients who previously used NSAIDs reported significantly fewer migrain...
